+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Encephalopathy Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

  • ID: 4830046
  • Drug Pipelines
  • August 2019
  • Region: Global
  • 61 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • BrainRepair UG
  • Celgene Corp
  • Chiesi Farmaceutici SpA
  • GW Pharmaceuticals Plc
  • Knopp Biosciences LLC
  • Mithra Pharmaceuticals SA
  • MORE
High levels of pipeline activity are being observed in Encephalopathy treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including BrainRepair UG, Celgene Corp, Chiesi Farmaceutici SpA, GW Pharmaceuticals Plc, Knopp Biosciences LLC and others.

A Significant contribution to the Encephalopathy pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Encephalopathy pipeline included 13 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Encephalopathy condition and increased access to investments is encouraging growth of Encephalopathy drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Encephalopathy drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Encephalopathy therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Encephalopathy pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Encephalopathy. Further, orphan drug status, fast track designation, grants awarded and other special status for Encephalopathy pipeline compounds are also included.

This study was produced independently by the publisher from their proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Encephalopathy pipeline and formulate effective research and development strategies.

Research Methodology

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Encephalopathy Pipeline candidates
  • Pre-clinical Phase: Discovery, research, pre-clinical
  • Early Phase: Phase 1 and Phase 2 Encephalopathy drugs
  • Late phase: Phase 3 and in-approval Encephalopathy drugs
Companies involved in the Pipeline
  • Company overview
  • Snapshot
  • Encephalopathy therapeutic treatment activities
Details for each Encephalopathy drug candidate
  • Snapshot
  • Drug Name
  • Alternative Names
  • Company
  • Originator
  • Phase
  • Molecule Type
  • Orphan Drug Status
  • Drug Overview
  • Mechanism of Action
  • Current Status
  • Trial Details
Other details
  • Pre-clinical trials for each drug candidate
  • Clinical trials for each drug candidate
Recent Encephalopathy therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • BrainRepair UG
  • Celgene Corp
  • Chiesi Farmaceutici SpA
  • GW Pharmaceuticals Plc
  • Knopp Biosciences LLC
  • Mithra Pharmaceuticals SA
  • MORE
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Encephalopathy- Disease Overview
2.2 Encephalopathy- Pipeline Snapshot
2.3 Encephalopathy- Pipeline Drugs by Phase
2.4 Encephalopathy- Pipeline Drugs by Company
2.5 Encephalopathy- Pipeline Drugs by Mechanism of Action

3 Company wise Pipeline Analysis
3.1 BrainRepair UG Encephalopathy Drug Pipeline, H2- 2019
3.2 Celgene Corp Encephalopathy Drug Pipeline, H2- 2019
3.3 Chiesi Farmaceutici SpA Encephalopathy Drug Pipeline, H2- 2019
3.4 GW Pharmaceuticals Plc Encephalopathy Drug Pipeline, H2- 2019
3.5 Knopp Biosciences LLC Encephalopathy Drug Pipeline, H2- 2019
3.6 Marinus Pharmaceuticals Inc Encephalopathy Drug Pipeline, H2- 2019
3.7 Mithra Pharmaceuticals SA Encephalopathy Drug Pipeline, H2- 2019
3.8 Pairnomix LLC Encephalopathy Drug Pipeline, H2- 2019
3.9 ProThera Biologics Inc Encephalopathy Drug Pipeline, H2- 2019
3.10 SciFluor Life Sciences LLC Encephalopathy Drug Pipeline, H2- 2019
3.11 Takeda Pharmaceutical Co Ltd Encephalopathy Drug Pipeline, H2- 2019
3.12 Therapicon Srl Encephalopathy Drug Pipeline, H2- 2019
3.13 Zynerba Pharmaceuticals Inc Encephalopathy Drug Pipeline, H2- 2019

4 Phase 1 Pipeline Drug Details
4.1 Encephalopathy- Phase 1 Drug Details
4.2 Encephalopathy- Phase 1 Drug Overview
4.3 Encephalopathy- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details

5 Phase 2 Pipeline Drug Details
5.1 Encephalopathy- Phase 2 Drug Details
5.2 Encephalopathy- Phase 2 Drug Overview
5.3 Encephalopathy- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details

6 Phase 3 Pipeline Drug Details
6.1 Encephalopathy- Phase 3 Drug Details
6.2 Encephalopathy- Phase 3 Drug Overview
6.3 Encephalopathy- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details

7 Pre-clinical Phase Pipeline Drug Details
7.1 Encephalopathy- Pre-clinical Phase Drug Details
7.2 Encephalopathy- Pre-clinical Phase Drug Overview
7.3 Encephalopathy- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details

8 Recent News and Developments

9 Appendix
9.1 About the Publisher
9.2 Sources and Research Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • BrainRepair UG
  • Celgene Corp
  • Chiesi Farmaceutici SpA
  • GW Pharmaceuticals Plc
  • Knopp Biosciences LLC
  • Marinus Pharmaceuticals Inc
  • Mithra Pharmaceuticals SA
  • Pairnomix LLC
  • ProThera Biologics Inc
  • SciFluor Life Sciences LLC
  • Takeda Pharmaceutical Co Ltd
  • Therapicon Srl
  • Zynerba Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll